Carlo Ballatore

Carlo Ballatore

Auto-generated profile, based on publicly available information

Carlo Ballatore

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2007 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
CBCarlo Ballatore
Carlo Ballatore
VLVirginia M.-Y. Lee
Virginia M.-Y. Lee
JTJohn Q. Trojanowski
John Q. Trojanowski

29 January 2013 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
CBCarlo Ballatore
Carlo Ballatore
DHDonna M. Huryn
Donna M. Huryn
ASAmos B. Smith
Amos B. Smith

14 March 2012 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
BZBin Zhang
Bin Zhang
JCJenna Carroll
Jenna Carroll
JTJohn Q. Trojanowski
John Q. Trojanowski
YYYuemang Yao
Yuemang Yao
MIMichiyo Iba
Michiyo Iba
KBKurt R. Brunden
Kurt R. Brunden
Neurodegenerative tauopathies, such as Alzheimer's disease (AD), are characterized by insoluble deposits of hyperphosphorylated tau protein within brain neurons. Increased phosphorylation and decreased solubility has been proposed to diminish normal tau stabilization of microtubules (MTs), thereby leading to neuronal dysfunction. Earlier studies have provided evidence that small molecule MT-stabilizing drugs that are used in the treatment of cancer may have utility in the treatment of tauopathies. However, it has not been established whether treatment with a small molecule MT-stabilizing compound will provide benefit in a transgenic model with pre-existing tau pathology, as would be seen in human patients with clinical symptoms. Accordingly, we describe here an interventional study of the brain-penetrant MT-stabilizing agent, epothilone D (EpoD), in aged PS19 mice with existing tau pathology and related behavioral deficits. EpoD treatment reduced axonal dystrophy and increased axonal MT density in the aged PS19 mice, which led to improved fast axonal transport and cognitive performance. Moreover, the EpoD-treated PS19 mice had less forebrain tau pathology and increased hippocampal neuronal integrity, with no dose-limiting side effects. These data reveal that brain-penetrant MT-stabilizing drugs hold promise for the treatment of AD and related tauopathies, and that EpoD could be a candidate for clinical testing.

13 October 2010 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
KBKurt R. Brunden
Kurt R. Brunden
BZBin Zhang
Bin Zhang
JCJenna Carroll
Jenna Carroll
YYYuemang Yao
Yuemang Yao
JPJustin S. Potuzak
Justin S. Potuzak
JTJohn Q. Trojanowski
John Q. Trojanowski
Neurons in the brains of those with Alzheimer's disease (AD) and many frontotemporal dementias (FTDs) contain neurofibrillary tangles comprised of hyperphosphorylated tau protein. Tau normally stabilizes microtubules (MTs), and tau misfolding could lead to a loss of this function with consequent MT destabilization and neuronal dysfunction. Accordingly, a possible therapeutic strategy for AD and related “tauopathies” is treatment with a MT-stabilizing anti-cancer drug such as paclitaxel. However, paclitaxel and related taxanes have poor blood–brain barrier permeability and thus are unsuitable for diseases of the brain. We demonstrate here that the MT-stabilizing agent, epothilone D (EpoD), is brain-penetrant and we subsequently evaluated whether EpoD can compensate for tau loss-of-function in PS19 tau transgenic mice that develop forebrain tau inclusions, axonal degeneration and MT deficits. Treatment of 3-month-old male PS19 mice with low doses of EpoD once weekly for a 3 month period significantly improved CNS MT density and axonal integrity without inducing notable side-effects. Moreover, EpoD treatment reduced cognitive deficits that were observed in the PS19 mice. These results suggest that certain brain-penetrant MT-stabilizing agents might provide a viable therapeutic strategy for the treatment of AD and FTDs.

30 March 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
PLPierrik Lassalas
Pierrik Lassalas
BGBryant Gay
Bryant Gay
CLCaroline Lasfargeas
Caroline Lasfargeas
MJMichael J. James
Michael J. James
VTVan Tran
Van Tran
CBCarlo Ballatore
Carlo Ballatore
The replacement of a carboxylic acid with a surrogate structure, or (bio)-isostere, is a classical strategy in medicinal chemistry. The general underlying principle is that by maintaining the features of the carboxylic acid critical for biological activity, but appropriately modifying the physicochemical properties, improved analogs may result. In this context, a systematic assessment of the physicochemical properties of carboxylic acid isosteres would be desirable to enable more informed decisions of potential replacements to be used for analog design. Herein we report the structure–property relationships (SPR) of 35 phenylpropionic acid derivatives, in which the carboxylic acid moiety is replaced with a series of known isosteres. The data set generated provides an assessment of the relative impact on the physicochemical properties that these replacements may have compared to the carboxylic acid analog. As such, this study presents a framework for how to rationally apply isosteric replacements of the carboxylic acid functional group.

1 July 2006 in Biochemistry
Verified
Journal Article
Closed access
YoungSoo KimYoungSoo Kim
YoungSoo Kim
ALAntonietta M. Lillo
Antonietta M. Lillo
SSSebastian C. J. Steiniger
Sebastian C. J. Steiniger
YLYing Liu
Ying Liu
CBCarlo Ballatore
Carlo Ballatore
§J§ Kim D. Janda
§ Kim D. Janda